清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Heterogeneous treatment effects of coronary artery bypass grafting in ischemic cardiomyopathy: A machine learning causal forest analysis

医学 心脏病学 内科学 危险系数 缺血性心肌病 动脉 心力衰竭 肌酐 射血分数 置信区间
作者
Zhuoming Zhou,Bohao Jian,Xuanyu Chen,Menghui Liu,Shaozhao Zhang,Guangguo Fu,Gang� Li,Mengya Liang,Ting Tian,Zhongkai Wu
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [Elsevier BV]
卷期号:168 (5): 1462-1471.e7 被引量:9
标识
DOI:10.1016/j.jtcvs.2023.09.021
摘要

Objectives We aim to evaluate the heterogeneous treatment effects of coronary artery bypass grafting in patients with ischemic cardiomyopathy and to identify a group of patients to have greater benefits from coronary artery bypass grafting compared with medical therapy alone. Methods Machine learning causal forest modeling was performed to identify the heterogeneous treatment effects of coronary artery bypass grafting in patients with ischemic cardiomyopathy from the Surgical Treatment for Ischemic Heart Failure trial. The risks of death from any cause and death from cardiovascular causes between coronary artery bypass grafting and medical therapy alone were assessed in the identified subgroups. Results Among 1212 patients enrolled in the Surgical Treatment for Ischemic Heart Failure trial, left ventricular end-systolic volume index, serum creatinine, and age were identified by the machine learning algorithm to distinguish patients with heterogeneous treatment effects. Among patients with left ventricular end-systolic volume index greater than 84 mL/m2 and age 60.27 years or less, coronary artery bypass grafting was associated with a significantly lower risk of death from any cause (adjusted hazard ratio, 0.61; 95% CI, 0.45-0.84) and death from cardiovascular causes (adjusted hazard ratio, 0.63; 95% CI, 0.45-0.89). By contrast, the survival benefits of coronary artery bypass grafting no longer exist in patients with left ventricular end-systolic volume index 84 mL/m2 or less and serum creatinine 1.04 mg/dL or less, or patients with left ventricular end-systolic volume index greater than 84 mL/m2 and age more than 60.27 years. Conclusions The current post hoc analysis of the Surgical Treatment for Ischemic Heart Failure trial identified heterogeneous treatment effects of coronary artery bypass grafting in patients with ischemic cardiomyopathy. Younger patients with severe left ventricular enlargement were more likely to derive greater survival benefits from coronary artery bypass grafting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xurilaixi完成签到,获得积分10
3秒前
4秒前
远离电刀完成签到,获得积分10
5秒前
lichunrong完成签到,获得积分10
10秒前
Ccc完成签到,获得积分10
44秒前
Henry完成签到,获得积分10
47秒前
李煜琛完成签到 ,获得积分10
55秒前
刚子完成签到 ,获得积分0
1分钟前
SciGPT应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
房天川完成签到 ,获得积分10
1分钟前
自信的高山完成签到 ,获得积分10
2分钟前
JamesPei应助生动的水池采纳,获得50
2分钟前
2分钟前
Elytra发布了新的文献求助10
2分钟前
2分钟前
ybwei2008_163发布了新的文献求助10
2分钟前
2分钟前
2分钟前
2分钟前
ybwei2008_163发布了新的文献求助10
2分钟前
香蕉觅云应助yyz采纳,获得30
2分钟前
cheqi完成签到 ,获得积分10
2分钟前
生动的水池完成签到,获得积分10
2分钟前
Lucas应助ybwei2008_163采纳,获得10
2分钟前
慕青应助ybwei2008_163采纳,获得10
2分钟前
3分钟前
清脆世界完成签到 ,获得积分10
3分钟前
yyz发布了新的文献求助30
3分钟前
3分钟前
Autin完成签到,获得积分10
3分钟前
ybwei2008_163发布了新的文献求助10
3分钟前
3分钟前
彭于晏应助科研通管家采纳,获得20
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
汉堡包应助科研通管家采纳,获得10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
3分钟前
Elytra完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
Adhesion Science: Principles & Practice 800
The Graphene Handbook (2019 Edition) 700
Signals, Systems, and Signal Processing 610
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6529876
求助须知:如何正确求助?哪些是违规求助? 8322692
关于积分的说明 17817479
捐赠科研通 5631320
什么是DOI,文献DOI怎么找? 2931848
邀请新用户注册赠送积分活动 1908421
关于科研通互助平台的介绍 1767724